References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailWhat are the most important medication attributes for patients with osteoporosis ? Results from a qualitative study
Hiligsmann, Mickaël ULg; Van Durme, C; Geusens, P et al

in Osteoporosis International (2012, March), 23(S2), 81-82

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailStructure modifying effects of strontium ranelate in knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiaensen, C et al

in Osteoporosis International (2012, March), 23(S2), 58-59

Detailed reference viewed: 127 (5 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis
Reginster, Jean-Yves ULg; Chapurlat, R; Christiansen, C et al

in Osteoporosis International (2012, March), 23(S2), 366-367

Detailed reference viewed: 43 (2 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate and risk of venous thromboembolism (VTE) : an update of a retrospective cohort study in the UK general practice research database (GPRD)
Cooper, C; Deltour, N; Speirs, C et al

in Osteoporosis International (2012, March), 23(S2), 364-365

Detailed reference viewed: 64 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate uncouples bone formation from bone resorption in male osteoporotic patients
COLLETTE, Julien ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2012, March), 23(S2), 365-366

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailPerception, knowledge and use by general practitioners of Belgium of the FRAX tool
Bruyère, Olivier ULg; Nicolet, Delphine ULg; Compère, Stéphanie et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 363-364

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailEffect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study
Bruyère, Olivier ULg; Zegels, Brigitte ULg; LEONORI, Lorenzo ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 362-363

Detailed reference viewed: 42 (8 ULg)
Full Text
Peer Reviewed
See detailSevere prevalent vertebral fractures predict subsequent vertebral and nonvertebral fractures: a 3-year prospective study
Bruyère, Olivier ULg; Roux, Christian; Nicolet, Delphine ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 361-362

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailAssessment of joint space narrowing in knee osteoarthritis has good long-term intercentre reproducibility when read in pairs with a semi-automated device
Gensburger, Deborah; DEROISY, Rita ULg; Arlot, Monique et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 247-248

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailRadiological and clinical profil of osteoarthritic patients undergoing of total joint replacement
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 129-130

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailLong-term (3 years) reproducibility for the radiological assessment of knee osteoarthritis
DEROISY, Rita ULg; Bruyère, Olivier ULg; Gensburger, Deborah et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 219-220

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailAn economic evaluation of strontium ranelate for the treatment of male osteoporosis
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 305-306

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Ben Sedrine, Wafa ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 312-313

Detailed reference viewed: 28 (5 ULg)
Full Text
Peer Reviewed
See detailFive years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension.
Papapoulos, S.; Chapurlat, R.; Libanati, C. et al

in Journal of Bone and Mineral Research (2012), 27(3), 694-701

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment of postmenopausal women with osteoporosis. Participants who completed FREEDOM were eligible to ... [more ▼]

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for treatment of postmenopausal women with osteoporosis. Participants who completed FREEDOM were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up to 10 years. For the extension results presented here, women from the FREEDOM denosumab group had 2 more years of denosumab treatment (long-term group) and those from the FREEDOM placebo group had 2 years of denosumab exposure (cross-over group). We report results for bone turnover markers (BTMs), bone mineral density (BMD), fractures rates, and safety. A total of 4550 women enrolled in the extension (2343 long-term; 2207 cross-over). Reductions in BTMs were maintained (long-term group) or occurred rapidly (cross-over group) following denosumab administration. In the long-term group, lumbar spine and total hip BMD increased further, resulting in 5-year gains of 13.7% and 7.0%, respectively. In the cross-over group, BMD increased at the lumbar spine (7.7%) and total hip (4.0%) during the 2-year denosumab treatment. Yearly fracture incidences for both groups were below rates observed in the FREEDOM placebo group and below rates projected for a "virtual untreated twin" cohort. Adverse events did not increase with long-term denosumab administration. Two adverse events in the cross-over group were adjudicated as consistent with osteonecrosis of the jaw (ONJ). Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile. (c) 2011 American Society for Bone and Mineral Research. [less ▲]

Detailed reference viewed: 27 (6 ULg)
Full Text
Peer Reviewed
See detailAssessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
Bruyère, Olivier ULg; Rizzoli, René; Coxam, V. et al

in Osteoporosis International (2012), 23

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and ... [more ▼]

Health claims for food products in Europe are permitted if the nutrient has been shown to have a beneficial nutritional or physiological effect. This paper defines health claims related to bone health and provides guidelines for the design and the methodology of clinical studies to support claims. [less ▲]

Detailed reference viewed: 56 (28 ULg)
Full Text
Peer Reviewed
See detailManagement of glucocorticoid-induced osteoporosis
Rizzoli, R.; Adachi, J. D.; Cooper, C. et al

in Calcified Tissue International (2012), 91(4), 225-243

This review summarizes the available evidence-based data that form the basis for therapeutic intervention and covers the current status of glucocorticoid-induced osteoporosis (GIOP) management, regulatory ... [more ▼]

This review summarizes the available evidence-based data that form the basis for therapeutic intervention and covers the current status of glucocorticoid-induced osteoporosis (GIOP) management, regulatory requirements, and risk-assessment options. Glucocorticoids are known to cause bone loss and fractures, yet many patients receiving or initiating glucocorticoid therapy are not appropriately evaluated and treated. An European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis workshop was convened to discuss GIOP management and to provide a report by a panel of experts. An expert panel reviewed the available studies that discussed approved therapeutic agents, focusing on randomized and controlled clinical trials reporting on bone mineral density and/or fracture risk of at least 48 weeks' duration. There is no evidence that GIOP and postmenopausal osteoporosis respond differently to treatments. The FRAX algorithm can be adjusted according to glucocorticoid dose. Available antiosteoporotic therapies such as bisphosphonates and teriparatide are efficacious in GIOP management. Several other agents approved for the treatment of postmenopausal osteoporosis may become available for GIOP. It is advised to stop antiosteoporotic treatment after glucocorticoid cessation, unless the patient remains at increased risk of fracture. Calcium and vitamin D supplementation as an osteoporosis-prevention measure is less effective than specific antiosteoporotic treatment. Fracture end-point studies and additional studies investigating specific subpopulations (pediatric, premenopausal, or elderly patients) would strengthen the evidence base and facilitate the development of intervention thresholds and treatment guidelines. © Springer Science+Business Media, LLC 2012. [less ▲]

Detailed reference viewed: 15 (5 ULg)